DEB - Dystrophic Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Conditions
Keywords
DEB, Dystrophic Epidermolysis Bullosa, COL7A1
Brief summary
This study is a non-interventional, observational study that will evaluate the natural history of wounds in patients with Dystrophic Epidermolysis Bullosa (DEB) for inclusion into the Krystal Biotech Phase III protocol of B-VEC (previously KB103). Wound recurrence and wound size will be evaluated for up to four months.
Detailed description
The objective of this study is to analyze the selected wounds' natural history prior to including the selected wounds in the evaluation of safety and efficacy in Krystal Biotech's Phase III protocol of B-VEC. Subjects will be enrolled upon obtaining consent and meeting eligibility criteria. Patient Screening is done on-site, followed by the imaging of at least 1 wound, but up to 15 wounds. All remaining imaging will be performed remotely with a smartphone or tablet application. Patients are on-trial for approximately four months.
Interventions
None listed
Sponsors
Stanford University
Krystal Biotech, Inc.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
No
Inclusion criteria
* Written informed consent is provided. Patients 18 years of age and older, and parent(s)/legal guardian(s) of patients younger than 18 years of age, must provide written informed consent prior to participating in the study; additionally, informed assent will be obtained from patients younger than 18 years of age as specified by local requirements. * Patient must have a documented diagnosis of DEB based on genetic analysis showing a mutation in COL7A1 or, in the opinion of the investigator, a confirmed diagnosis of DEB based on histologic criteria (antigen mapping or electron microscopy). * Age: 6 months and older * Patient must have at least 1 wound that is suitable for imaging, in the opinion of the investigator, at the time of enrollment. * Patient is willing and able to undergo the protocol-specified procedures.
Exclusion criteria
* In the opinion of the investigator, inclusion poses an unacceptable risk to the patient or interpretation of these study data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in wound surface area | Up to four months | Percent change in wound surface area from baseline will be measured from images uploaded to an imaging application. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Closure | Up to four months | The time it takes for a wound to completely close. |
| Duration of wound closure | Up to four months | If a closure occurs, the time a wound remains epithelialized after the first, and any subsequent closures. |
Countries
United States
Outcome results
None listed